Research
Energy balance
Tirzepatide facilitated an average 18.5% weight loss (>46 pounds) in overweight and obese patients with type 1 diabetes at 1 year.
Practitioners may consider tirzepatide as an effective option for weight management in this patient population.
StrongSupportsmedium confidence
In this pilot (off label) study, we conclude that tirzepatide facilitated an average 18.5% weight loss (>46 pounds) and improved glucose control in OW/OB patients with T1D at 1 year.
Why this rating
Based on study design from abstract.
Source
Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes
Satish K. Garg et al. · Diabetes Technology & Therapeutics · 2024
DOI 10.1089/dia.2024.0050
cohort · n=62Cited 57×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →